The funds will allow the company to continue a Phase I/II trial of its CDK2 inhibitor in certain hard-to-treat biomarker-defined cancers.

NEW YORK – GSK will roll out its anti-PD-1 therapy Jemperli (dostarlimab) for certain endometrial cancer patients and its PARP inhibitor Zejula (niraparib) for ovarian cancer patients in India.

Collaborators from various institutions will leverage the latest multi-disciplinary drug development tools to produce tailored treatment and prevention strategies.